Healthtech company Berry Street is raising investment to scale its clinical metabolic health platform, which combines GLP-1 therapy, AI support, and a network of licensed dietitians with coverage through insurance programs.
The project is focused on the US market and operates in the segment of obesity treatment and related metabolic conditions. According to the company, obesity is one of the largest systemic challenges for the US healthcare system: direct annual costs are estimated at $480 billion, while around 40% of the adult population in the United States suffers from obesity.
Berry Street positions itself as an integrated clinical platform designed to address one of the key challenges of GLP-1 therapy — the lack of long-term clinical support for patients. The platform combines three core components: prescription of GLP-1 medications, AI dietitian Ria, and a network of more than 2,000 licensed dietitians across all 50 US states.
According to the company, the platform works with FDA-approved medications from Lilly and Novo Nordisk, integrates with medical records, laboratory data, wearables, and CGM devices, and supports AI-powered patient guidance in 95 languages.
The company has already built an insurance network covering around 195 million insured individuals, including approximately 135 million commercially insured and 60 million publicly insured people. Its partners and contracts include Cigna, UnitedHealthcare, Aetna, more than 30 Blue Cross Blue Shield branches, and 120 group contracts.
As of January 2026, Berry Street reports more than $70 million in ARR, 175,000 patients, and over 1 million appointments since 2023. The company’s revenue increased from $2 million in FY2023 to $45 million in 2025, while the forecast for 2026 exceeds $80 million.
In 2026–2029, the company plans further revenue growth: more than $160 million in 2027, over $330 million in 2028, and more than $500 million in 2029. EBITDA breakeven is expected in 2027, while from 2028 the company forecasts an EBITDA margin of over 15%.
The investment offer provides for participation in equity through a venture capital model without dividend payments. Potential investor returns are expected to come from the growth of the company’s valuation and the subsequent sale of the stake. The minimum investment amount is $10,000, with the participation deadline set for June 14, 2026.
Among the potential exit scenarios are a strategic acquisition by major healthcare players or insurers, an IPO by 2029, and participation in the consolidation of the digital metabolic health market. The potential investment multiple, according to the project’s estimates, could reach around 6x under favorable market conditions.
More detailed information is available on the InVenture platform.
